SELECT MEDICAL HOLDINGS CORP — fact timeline

SELECT MEDICAL HOLDINGS CORP reported first quarter ended March 31, 2026 results: revenue $1,421.5 million, net income $63.8 million, EPS $0.35.

“For the first quarter ended March 31, 2026, revenue increased 5.0% to $1,421.5 million, compared to $1,353.2 million for the same quarter, prior year. Income from operations was $98.4 million for the first quarter ended March 31, 2026, compared to $112.7 million for the same quarter, prior year. Net income was $63.8 million for the first quarter ended March 31, 2026, compared to $74.7 million for the same quarter, prior year. Adjusted EBITDA was $141.6 million for the first quarter ended March 31, 2026, compared to $151.4 million for the same quarter, prior year. Earnings per common share was $0.35 for the first quarter ended March 31, 2026, compared to $0.44 for the same quarter, prior year.”

SELECT MEDICAL HOLDINGS CORP: Board adopted Amended and Restated Bylaws enhancing stockholder nomination and proposal procedures, including universal proxy rule compliance requirements (effective 2025-07-30).

“On July 30, 2025, the Board of Directors (the “Board”) of Select Medical Holdings Corporation (the “Company”) approved and adopted amendments to the Company’s bylaws, amending and restating them in their entirety (the “Amended and Restated Bylaws”).”

SELECT MEDICAL HOLDINGS CORP: Reduced voting threshold to a majority of outstanding shares to amend the Bylaws and remove a Director for cause, effective upon the Charter amendment (effective 2025-04-28).

“The Board previously also approved an amendment to the Bylaws, which became effective upon the effectiveness of the foregoing amendment to the Charter.”

SELECT MEDICAL HOLDINGS CORP: Eliminated supermajority voting requirements from the Charter, reducing voting threshold to a majority of outstanding shares to amend the Bylaws and certain enumerated provisions of the Charter (effective 2025-04-28).

“The amendment of the Charter became effective upon the filing of a certificate of amendment with the Delaware Secretary of State on April 28, 2025.”

David S. Chernow was appointed as director at SELECT MEDICAL HOLDINGS CORP.

“On July 31, 2024, the Board of Directors (the “Board”) of the Company appointed David S. Chernow as a director of the Company, effective August 1, 2024, in order to fill the vacancy created by Mr. Ortenzio’s resignation.”

Rocco A. Ortenzio resigned as director at SELECT MEDICAL HOLDINGS CORP.

“Rocco A. Ortenzio, a director of Select Medical Holdings Corporation (the “Company”), notified the Company of his decision to resign as a director, effective August 1, 2024.”

SELECT MEDICAL HOLDINGS CORP reported for its first quarter ended March 31, 2024 results: revenue increased 7.4% to $1,788.8 million, net income increased 37.4% to $117.2 million, EPS increased 33.9% to $0.75.

“SEM) today announced results for its first quarter ended March 31, 2024, and the declaration of a cash dividend. For the first quarter ended March 31, 2024, revenue increased 7.4% to $1,788.8 million, compared to $1,665.0 million for the same quarter, prior year. Income from operations increased 28.1% to $194.0 million for the first quarter ended March”

SELECT MEDICAL HOLDINGS CORP: Amended certificate of incorporation to permit officer exculpation under Delaware law (effective 2024-04-26).

“The amendment of Charter became effective upon the filing of a certificate of amendment with the Delaware Secretary of State on April 26, 2024.”

SELECT MEDICAL HOLDINGS CORP shareholders approved Non-Binding Advisory Vote on Stockholder’s Simple Majority Proposal.

“Proposal 6 : Non-Binding Advisory Vote on Stockholder’s Simple Majority Proposal Votes For Votes Against Abstentions Broker Non-Votes 74,680,241 46,242,865 23,652 2,545,553”

SELECT MEDICAL HOLDINGS CORP shareholders approved Approval of Amendment to the Company’s Amended and Restated Certificate of Incorporation To Permit the Exculpation of Officers of the Company.

“Proposal 5 : A pproval of Amendment to the Company’s Amended and Restated Certificate of Incorporation To Permit the Exculpation of Officers of the Company Votes For Votes Against Abstentions Broker Non-Votes 116,474,404 4,352,165 119,189 2,545,553”

SELECT MEDICAL HOLDINGS CORP shareholders approved Ratification of the Appointment of PricewaterhouseCoopers LLP as the Company’s Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2024 at the 2024-12-31 meeting.

“Proposal 4 : Ratification of the Appointment of PricewaterhouseCoopers LLP as the Company’s Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2024 Votes For Votes Against Abstentions Broker Non-Votes 122,477,547 987,844 26,920 0”

SELECT MEDICAL HOLDINGS CORP shareholders approved Approval of Amendment to the Company’s 2020 Equity Incentive Plan to Increase the Total Share Reserve and Add a Minimum Vesting Period.

“Proposal 3 : A pproval of Amendment to the Company’s 2020 Equity Incentive Plan to Increase the Total Share Reserve and Add a Minimum Vesting Period Votes For Votes Against Abstentions Broker Non-Votes 119,196,980 1,718,471 31,307 2,545,553”

SELECT MEDICAL HOLDINGS CORP shareholders approved Non-Binding Advisory Vote on the Compensation of the Company’s Named Executive Officers.

“Proposal 2 : Non-Binding Advisory Vote on the Compensation of the Company’s Named Executive Officers Votes For Votes Against Abstentions Broker Non-Votes 106,777,980 14,125,946 42,832 2,545,553”

SELECT MEDICAL HOLDINGS CORP shareholders approved Election of Three Class III Directors to the Board of Directors.

“Proposal 1 : The Election of Three Class III Directors to the Board of Directors Name Votes For Votes Against Abstentions Broker Non-Votes James S. Ely III 102,880,768 18,037,258 28,732 2,545,553 Rocco A. Ortenzio 114,949,540 5,968,478 28,740 2,545,553 Thomas A. Scully 114,375,405 6,542,501 28,852 2,545,553”

SELECT MEDICAL HOLDINGS CORP reported year ended December 31, 2023 results: revenue $6,664.1 million, net income $299.7 million, EPS $1.91.

“For the year ended December 31, 2023, revenue increased 5.2% to $6,664.1 million, compared to $6,333.5 million for the prior year.”

SELECT MEDICAL HOLDINGS CORP reported fourth quarter ended December 31, 2023 results: revenue $1,658.9 million, net income $61.8 million, EPS $0.36.

“For the fourth quarter ended December 31, 2023, revenue increased 4.9% to $1,658.9 million, compared to $1,581.5 million for the same quarter, prior year.”

SELECT MEDICAL HOLDINGS CORP reported third quarter ended September 30, 2023 results: revenue $1,665.7 million, net income $60.8 million, EPS $0.38.

“For the third quarter ended September 30, 2023, revenue increased 6.2% to $1,665.7 million, compared to $1,567.8 million for the same quarter, prior year. Income from operations increased 42.1% to $130.0 million for the third quarter ended September 30, 2023, compared to $91.5 million for the same quarter, prior year. For the third quarter ended September 30, 2023, income from operations included $0.5 million of other operating income, compared to $8.4 million of other operating income for the same quarter, prior year. The other operating income for the third quarter ended September 30, 2022, was principally related to the recognition of payments received under the Coronavirus Aid, Relief, and Economic Security Act Public Health and Social Services Emergency Fund, also referred to as the Provider Relief Fund. Net income increased 59.5% to $60.8 million for the third quarter ended September 30, 2023, compared to $38.1 million for the same quarter, prior year. Adjusted EBITDA increased 2”

Martin F. Jackson changed role as Chief Financial Officer at SELECT MEDICAL HOLDINGS CORP.

“Martin F. Jackson will no longer serve as Chief Financial Officer of Select as of October 1, 2023, but will continue to serve as Senior Executive Vice President of Strategic Finance and Operations.”

Michael F. Malatesta was appointed as Chief Financial Officer at SELECT MEDICAL HOLDINGS CORP.

“Select also announced the appointment of Michael F. Malatesta, 54, as the Chief Financial Officer of Select, effective October 1, 2023.”

David Chernow changed role as President at SELECT MEDICAL HOLDINGS CORP.

“David Chernow will no longer serve as President of Select as of October 1, 2023, but will continue to serve as Chief Executive Officer.”

Thomas P. Mullin was appointed as Co-President at SELECT MEDICAL HOLDINGS CORP.

“Select Medical Holdings Corporation, a Delaware corporation (“Select”), announced the appointments of John A. Saich, 55, and Thomas P. Mullin, 39, as Co-Presidents, effective October 1, 2023.”

John A. Saich was appointed as Co-President at SELECT MEDICAL HOLDINGS CORP.

“Select Medical Holdings Corporation, a Delaware corporation (“Select”), announced the appointments of John A. Saich, 55, and Thomas P. Mullin, 39, as Co-Presidents, effective October 1, 2023.”

SELECT MEDICAL HOLDINGS CORP amended Select Credit Agreement with JPMorgan Chase Bank, N.A. valued at increases the revolving credit commitments available under the Select Credit Agreement from $710.0 m (effective 2023-08-31).

“Amendment No. 9 to the Select Credit Agreement On August 31, 2023, Select Medical Corporation (“ Select ”) and Select Medical Holdings Corporation (“ Holdings ”) entered into Amendment No. 9 (the “ Select Amendment ”) to that certain Credit Agreement, dated as of March 6, 2017, by and among Holdings, Select, the lenders and issuing banks party thereto from time to time and JPMorgan Chase Bank, N.A. (“ JPMorgan ”), as administrative agent and collateral agent (as amended by Amendment No. 1, dated as of March 22, 2018, Amendment No. 2 dated as of October 26, 2018, Amendment No. 3, dated as of August 1, 2019, Amendment No. 4, dated as of December 10, 2019, Amendment No. 5, dated as of June 2, 2021, Amendment No. 6, dated as of February 21, 2023, Amendment No. 7, dated as of May 31, 2023, Amendment No. 8, dated as of July 31, 2023 and the Select Amendment, the “ Select Credit Agreement ”). Among other things, the Select Amendment increases the revolving credit commitments available under t”

SELECT MEDICAL HOLDINGS CORP reported second quarter ended June 30, 2023 results: revenue $1,674.5 million, net income $91.9 million, EPS $0.61.

“For the second quarter ended June 30, 2023, revenue increased 5.7% to $1,674.5 million, compared to $1,584.7 million for the same quarter, prior year.”

Bryan C. Cressey resigned as Director at SELECT MEDICAL HOLDINGS CORP.

“Bryan C. Cressey, a director of the Select Medical Holdings Corporation (the “Company”) and chairman of the Compensation Committee (the “Compensation Committee”) of the Company’s Board of Directors, notified the Company of his decision to resign as a director, effective August 2, 2023.”

SELECT MEDICAL HOLDINGS CORP amended Amendment No. 8 to the Select Credit Agreement with Select Medical Corporation, Select Medical Holdings Corporation, and JPMorgan Chase Bank, N.A. as administrative agent valued at New tranche of refinancing term loans of $2,103.0 million, replacement revolving credit facility of (effective 2023-07-31).

“On July 31, 2023, Select Medical Corporation (“ Select ”) and Select Medical Holdings Corporation (“ Holdings ”) entered into Amendment No. 8 (the “ Select Amendment ”) to that certain Credit Agreement, dated as of March 6, 2017, by and among Holdings, Select, the lenders and issuing banks party thereto from time to time and JPMorgan Chase Bank, N.A. (“ JPMorgan ”), as administrative agent and collateral agent (as amended by Amendment No. 1, dated as of March 22, 2018, Amendment No. 2 dated as of October 26, 2018, Amendment No. 3, dated as of August 1, 2019, Amendment No. 4, dated as of December 10, 2019, Amendment No. 5, dated as of June 2, 2021, Amendment No. 6, dated as of February 21, 2023, Amendment No. 7, dated as of May 31, 2023, and the Select Amendment, the “ Select Credit Agreement ”). Among other things, the Select Amendment (i) provides for a new tranche of refinancing term loans in an aggregate principal amount of $2,103.0 million to replace the existing tranche of term lo”

SELECT MEDICAL HOLDINGS CORP reported second quarter ended June 30, 2023 results: revenue approximately $1.67 billion, EPS approximately $0.61.

“Select Medical expects its net operating revenue for its second quarter of 2023 to be approximately $1.67 billion. Select Medical expects earnings excluding interest, income taxes, depreciation and amortization, gain (loss) on early retirement of debt, stock compensation expense, gain (loss) on sale of businesses, and equity in earnings (losses) of unconsolidated subsidiaries, or Adjusted EBITDA, for the second quarter of 2023 to be approximately $219 million. Select Medical expects fully diluted earnings per common share for the second quarter of 2023 to be approximately $0.61.”

SELECT MEDICAL HOLDINGS CORP reported first quarter ended March 31, 2023 results: revenue $1,665.0 million, net income $85.3 million, EPS $0.56.

“For the first quarter ended March 31, 2023, revenue increased 4.1% to $1,665.0 million, compared to $1,599.5 million for the same quarter, prior year. Income from operations increased 45.7% to $151.5 million for the first quarter ended March 31, 2023, compared to $104.0 million for the same quarter, prior year. Net income increased 52.4% to $85.3 million for the first quarter ended March 31, 2023, compared to $55.9 million for the same quarter, prior year. Adjusted EBITDA increased 30.6% to $214.1 million for the first quarter ended March 31, 2023, compared to $163.8 million for the same quarter, prior year. Earnings per common share increased 51.3% to $0.56 for the first quarter ended March 31, 2023, compared to $0.37 for the same quarter, prior year.”

SELECT MEDICAL HOLDINGS CORP shareholders approved Ratification of the Appointment of PricewaterhouseCoopers LLP as the Company’s Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2023 at the 2023-04-27 meeting.

“Proposal 4 : Ratification of the Appointment of PricewaterhouseCoopers LLP as the Company’s Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2023 Votes For Votes Against Abstentions Broker Non-Votes 123,337,745 760,759 222,024 0”

SELECT MEDICAL HOLDINGS CORP shareholders approved Non-Binding Advisory Vote on the Frequency of the Non-Binding Advisory Vote on the Compensation of the Company’s Named Executive Officers at the 2023-04-27 meeting.

“Proposal 3 : Non-Binding Advisory Vote on the Frequency of the Non-Binding Advisory Vote on the Compensation of the Company’s Named Executive Officers 1 Year 2 Years 3 Years Abstentions Broker Non-Votes 116,335,529 13,915 5,135,199 1,306,327 1,529,558”

SELECT MEDICAL HOLDINGS CORP shareholders approved Non-Binding Advisory Vote on the Compensation of the Company's Named Executive Officers at the 2023-04-27 meeting.

“Proposal 2 : Non-Binding Advisory Vote on the Compensation of the Company’s Named Executive Officers Votes For Votes Against Abstentions Broker Non-Votes 107,662,511 14,902,617 225,842 1,529,558”

SELECT MEDICAL HOLDINGS CORP shareholders approved Election of Four Class II Directors to the Board of Directors at the 2023-04-27 meeting.

“Proposal 1 : The Election of Four Class II Directors to the Board of Directors Name Votes For Votes Against Abstentions Broker Non-Votes Bryan C. Cressey 106,731,681 15,841,100 218,189 1,529,558 Parvinderjit S. Khanuja 122,036,170 535,660 219,140 1,529,558 Robert A. Ortenzio 115,564,005 7,008,274 218,691 1,529,558 Daniel J. Thomas 116,300,524 6,272,561 217,885 1,529,558”

Christopher S. Weigl was appointed as Senior Vice President, Controller & Chief Accounting Officer at SELECT MEDICAL HOLDINGS CORP.

“Effective March 1, 2023, the Board of Directors (the “Board”) of Select appointed Christopher S. Weigl, 39, as Senior Vice President, Controller & Chief Accounting Officer.”

Scott A. Romberger resigned as Chief Accounting Officer at SELECT MEDICAL HOLDINGS CORP.

“Effective March 1, 2023, Scott A. Romberger resigned from his position as Chief Accounting Officer of Select Medical Holdings Corporation, a Delaware corporation (“Select”).”

SELECT MEDICAL HOLDINGS CORP reported year ended December 31, 2022 results: revenue $6,333.5 million, net income $198.0 million, EPS $1.23.

“For the year ended December 31, 2022, revenue increased 2.1% to $6,333.5 million, compared to $6,204.5 million for the prior year. Income from operations was $403.3 million for the year ended December 31, 2022, compared to $713.8 million for the prior year. For the years ended December 31, 2022 and 2021, income from operations included $23.8 million and $123.8 million, respectively, of other operating income related to the recognition of payments received under the Provider Relief Fund. Net income was $198.0 million for the year ended December 31, 2022, compared to $499.9 million for the prior year. For the year ended December 31, 2021, net income included pre-tax gains on sales of businesses of $2.2 million. Adjusted EBITDA was $646.9 million for the year ended December 31, 2022, compared to $947.4 million for the prior year. Earnings per common share was $1.23 for the year ended December 31, 2022, compared to $2.98 for the prior year.”

SELECT MEDICAL HOLDINGS CORP reported fourth quarter ended December 31, 2022 results: revenue $1,581.5 million, net income $37.7 million, EPS $0.22.

“For the fourth quarter ended December 31, 2022, revenue increased 1.4% to $1,581.5 million, compared to $1,559.8 million for the same quarter, prior year. Income from operations increased 12.0% to $86.9 million for the fourth quarter ended December 31, 2022, compared to $77.5 million for the same quarter, prior year. For the fourth quarters ended December 31, 2022 and 2021, income from operations included $0.6 million and $8.0 million, respectively, of other operating income related to the recognition of payments received under the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) Public Health and Social Services Emergency Fund, also referred to as the Provider Relief Fund. Net income was $37.7 million for the fourth quarter ended December 31, 2022, compared to $66.3 million for the same quarter, prior year. For the fourth quarter ended December 31, 2021, net income included a pre-tax gain on sale of businesses of $2.2 million. Adjusted EBITDA increased 7.6% to $148.9 m”

SELECT MEDICAL HOLDINGS CORP amended Amendment No. 6 to the Select Credit Agreement with JPMorgan Chase Bank, N.A., as administrative agent (effective 2023-02-21).

“On February 21, 2023, Select Medical Corporation (“ Select ”) and Select Medical Holdings Corporation (“ Holdings ”) entered into Amendment No. 6 (the “ Select Amendment ”) to that certain Credit Agreement, dated as of March 6, 2017, by and among Holdings, Select, the lenders and issuing banks party thereto from time to time and JPMorgan Chase Bank, N.A. (“ JPMorgan ”), as administrative agent and collateral agent (as amended by Amendment No. 1, dated as of March 22, 2018, Amendment No. 2 dated as of October 26, 2018, Amendment No. 3, dated as of August 1, 2019, Amendment No. 4, dated as of December 10, 2019, Amendment No. 5, dated as of June 2, 2021 and the Select Amendment, the “ Select Credit Agreement ”).”

SELECT MEDICAL HOLDINGS CORP reported nine months ended September 30, 2022 results: revenue $4,752.1 million, net income $160.3 million, EPS $1.01.

“For the nine months ended September 30, 2022, revenue increased 2.3% to $4,752.1 million, compared to $4,644.7 million for the same period, prior year.”

SELECT MEDICAL HOLDINGS CORP reported third quarter ended September 30, 2022 results: revenue $1,567.8 million, net income $38.1 million, EPS $0.21.

“Select Medical Holdings Corporation (“Select Medical,” “we,” “us,” or “our”) (NYSE: SEM) today announced results for its third quarter ended September 30, 2022, and the declaration of a cash dividend. For the third quarter ended September 30, 2022, revenue increased 2.2% to $1,567.8 million, compared to $1,534.2 million for the same quarter, prior year.”

Parvinderjit Singh Khanuja was appointed as director at SELECT MEDICAL HOLDINGS CORP.

“On November 2, 2021, the Board of Directors (the “Board”) of Select Medical Holdings Corporation (“Select”) appointed Parvinderjit Singh Khanuja, MD, FACP as a director of Select, effective November 1, 2021.”